BBPOS
BBPOS has announced the launch of WisePadTM 2; advanced technology developed by innovative engineers. The WisePadTM 2 can be used in an integrated or semi-integrated POS environment as well as a stand-alone environment connecting to the payment processor or gateway via GPRS, 3G or Wi-Fi.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160525005100/en/
WisePadTM 2 reads EMV chip card, triple track magnetic stripe card, NFC card and has a secured PIN pad. Compact and lightweight at 3.7oz (105g), it is mobile and flexible. The WisePadTM 2 also has standard over-the-air features allowing both firmware updates and key injection that are essential in increasing operational efficiency as well as having a 2G/3G modem to allow direct connectivity to the network.
WisePadTM 2 complies with all major industrial security standards including PCI PTS v4.1 with SRED; EMV L1 & L2; EMV Contactless L1; VISA payWave; MasterCard PayPass; AMEX ExpressPay; Discover D-PAS; and MasterCard TQM.
WisePadTM 2 will be widely adopted as a mobile solution working with a smart device or as a stand-alone solution. It will also be a good alternative to conventional counter-top POS devices in countries which use Chip and PIN payment systems, such as China and in Europe. The non-NFC versions have been used at a number of key events and by merchants. For example, at the Dubai World Cup, customers had the flexibility and convenience of not waiting in long queues to purchase tickets and, instead, were able to use their debit or credit cards via roaming staff who were using tablets and WisePadTM .
WisePadTM 2 is the future of mPOS - delivering a cost effective solution with convenient updating and a wide range of applications. Please visit our website for more details.
BBPOS
www.bbpos.com
WisePadTM
2
http://bbpos.com/files/bbproducts/11-WP2_A4_Catalogue_20160523.pdf
About BBPOS
Founded in 2008, BBPOS is an mPOS solution provider headquartered in Hong Kong with regional offices in San Jose, Miami, London, Singapore and Shanghai. The business invented the mobile payment audio jack at a time when smart phones were in their infancy. Today, we are respected as a leading innovator, designer, and manufacturer of end-to-end mobile POS solutions, serving key sectors including mobile merchant, retail, hospitality, delivery, transport and government.
Our world-class engineering team has developed a family of innovative POS devices that deliver quality solutions while implementing the highest security standards. Our products are designed with the flexibility to securely manage any transaction, in any environment, anywhere in the world. In March 2016, mPOS tracker ranked BBPOS 6th among 212 global payment industry players with a high score of 70.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160525005100/en/
Contact:
BBPOS
Gloria Chan, +852-3907-0305
gloria.chan@bbpos.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom